Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zymeworks (ZYME) EBIT (2021 - 2025)

Zymeworks' EBIT history spans 5 years, with the latest figure at -$44.2 million for Q4 2025.

  • On a quarterly basis, EBIT fell 98.73% to -$44.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$92.5 million, a 32.5% increase, with the full-year FY2025 number at -$92.5 million, up 32.5% from a year prior.
  • EBIT hit -$44.2 million in Q4 2025 for Zymeworks, down from -$22.1 million in the prior quarter.
  • Over the last five years, EBIT for ZYME hit a ceiling of $319.4 million in Q4 2022 and a floor of -$72.7 million in Q1 2022.
  • Historically, EBIT has averaged -$18.8 million across 5 years, with a median of -$36.0 million in 2024.
  • Biggest five-year swings in EBIT: soared 881.89% in 2022 and later plummeted 107.33% in 2023.
  • Tracing ZYME's EBIT over 5 years: stood at -$40.8 million in 2021, then soared by 881.89% to $319.4 million in 2022, then plummeted by 107.33% to -$23.4 million in 2023, then grew by 5.14% to -$22.2 million in 2024, then tumbled by 98.73% to -$44.2 million in 2025.
  • Business Quant data shows EBIT for ZYME at -$44.2 million in Q4 2025, -$22.1 million in Q3 2025, and -$674000.0 in Q2 2025.